Inbar

Liminal Raises $17.5 Million in Series A2 Funding to Catalyze Production of Safe, Reliable, High-Quality EV Batteries

Retrieved on: 
Monday, February 6, 2023
Technology, Batteries, EV, Electric Vehicles, Automotive, Original equipment manufacturer, Serie A2 (basketball), Inbar, Dow Chemical Company, Safety, Entrepreneurship, Cell, Engineering, University, Intelligence, EVS, Renewable energy, Northvolt

Liminal will use this funding to scale its EchoStat® inspection systems into factory-integrated solutions for global battery manufacturers, tapping into the rapidly growing demand for safe, reliable, and more affordable EV batteries.

Key Points: 
  • Liminal will use this funding to scale its EchoStat® inspection systems into factory-integrated solutions for global battery manufacturers, tapping into the rapidly growing demand for safe, reliable, and more affordable EV batteries.
  • "Our mission is to catalyze a clean energy future in which EVs are the default option for everyone,” said Liminal CEO and Co-Founder, Andrew Hsieh.
  • “Our products help battery manufacturers hit their aggressive production volume and cost targets, while ensuring their cells meet stringent EV safety and performance requirements.
  • More information about careers with Liminal can be found at Liminal Careers .

Wallarm Expands Executive Leadership Team to Support Rapid Growth

Retrieved on: 
Wednesday, November 23, 2022
Security, Apps, Applications, Technology, Software, Networks, Internet, Schneider National, API, FP, Acronis, Secrecy, Web API security, Inbar, Strategic planning, CFO, EY, Aspect Software, Smart card application protocol data unit, SOX, Research, Application, Liverpool Victoria, NetJets, Blog, Growth, Sun Microsystems, Organization, DevOps, Risk management, Computer security, Security, Management, Fine chemical, United Airlines

Wallarm , the end-to-end API security company, is excited to announce several additions to the executive leadership team to help guide Wallarms strategic growth in the API security market, which is expected to exceed $10B in the next decade.

Key Points: 
  • Wallarm , the end-to-end API security company, is excited to announce several additions to the executive leadership team to help guide Wallarms strategic growth in the API security market, which is expected to exceed $10B in the next decade.
  • The addition of Adi, Michael and Tim to our executive management team enables us to deliver on the opportunity in front of us and will take us through our next stage of growth and beyond, stated Ivan Novikov, CEO and co-founder of Wallarm.
  • It is an honor to join such a cutting-edge and groundbreaking hyper-growth company and its amazing team, said Ebbers.
  • Wallarm end-to-end API security products provide robust protection for APIs, web applications , microservices, and serverless workloads running in cloud-native environments.

Israel's Mileutis Strengthens Board of Directors with New Appointments

Retrieved on: 
Tuesday, January 18, 2022
Entrepreneurship, Technology, Veterinarian, Science and technology in Asia, Board of directors, Montbéliarde, Mastitis, SCR, Imilac, Product management, CEO, Ori, Merck, Merrill (company), Farmer, Veteran, Time, Marketing, NESS, Merck & Co., Board, Investment, Milk, Management, Pharmaceutical industry, Research, Inbar

NESS ZIONA, Israel, Jan. 18, 2022 /PRNewswire/ -- Mileutis , an Israeli-based biopharmaceutical company revolutionizing how farmers and veterinarians treat a range of diseases, today announced the appointment of two new executives to its Board of Directors.

Key Points: 
  • NESS ZIONA, Israel, Jan. 18, 2022 /PRNewswire/ -- Mileutis , an Israeli-based biopharmaceutical company revolutionizing how farmers and veterinarians treat a range of diseases, today announced the appointment of two new executives to its Board of Directors.
  • The appointment of two seasoned veterans with strong financial, product development, sales, marketing, and agritech experience puts Mileutis in a strong position to tap into the multi-billion-dollar global mastitis market.
  • "To have such leaders join the Mileutis Board of Directors is significant and illustrates the ambitious goals of the organization to invest in people and technology that will have a significant impact in the sector.
  • Mileutis' first product Imilacis aimed at dairy cows, providing a residue-free non-antibiotic therapy for prevention and treatment of mastitis at dry-off.

CYE Expands Senior Management Leadership, Including National Security Experts, to Support Hyper-Growth

Retrieved on: 
Tuesday, October 12, 2021
IDF, Ministry of Defense (Israel), D, TEL, CPO, ECI Telecom, VP, Nimrod, Investment, CYE, Data science, Risk management, Inbar, Knowledge, Professional, CEO, CYREN, Solution, Shmulik Perlman, Imperva, Ministry, Research, CTI, Technology, Management, Medical device

TEL AVIV, Israel, Oct. 12, 2021 /PRNewswire/ -- CYE, the cyber solutions industry leader, today announced senior management appointments as part of its ongoing global expansion. The senior managers are all cybersecurity and/or national-level security experts who have held prominent positions in corporate and governmental organizations.

Key Points: 
  • The senior managers are all cybersecurity and/or national-level security experts who have held prominent positions in corporate and governmental organizations.
  • Prior to joining CYE, Inbar served in several senior product management and R&D roles in companies such as Varonis, Fortscale, and more, where she developed advanced intelligence and cybersecurity products.
  • Dr. Nimrod Partush, VP Data Science at CYE,combines years of experience in AI research and deep knowledge of the cybersecurity domain.
  • CYE serves as a trusted advisor to medium-size and Fortune 500 companies in multiple industries around the world.

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

Retrieved on: 
Wednesday, July 7, 2021
Organizations, Bamboo, International Bamboo and Rattan Organisation, LinkedIn, Inbar

TEL AVIV, IsraelandBETHESDA,Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.

Key Points: 
  • TEL AVIV, IsraelandBETHESDA,Md., July 7, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has appointed Dr. Inbar Maymon-Pomeranchik to its Board of Directors as an Independent Director.
  • We look forward to working with Inbar towards expanding our technological capabilities laterally into new and emerging market opportunities."
  • Dr. Inbar Maymon-Pomeranchik noted "It is a great honor to join the Board of Directors of Cannabics Pharmaceuticals.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

AVIDA Global Strengthens Management Team Following £1.9M Raise

Retrieved on: 
Tuesday, February 25, 2020
Organizations, International Bamboo and Rattan Organisation, Inbar, Avida, Articles

Dr. Inbar Maymon-Pomeranchik, one of the world's leading experts on medicinal cannabis, joins AVIDA Global's advisory board.

Key Points: 
  • Dr. Inbar Maymon-Pomeranchik, one of the world's leading experts on medicinal cannabis, joins AVIDA Global's advisory board.
  • Speaking of her role, David Kirby, CEO, AVIDA Global, said: "Dr. Inbar Maymon-Pomeranchik has been working with us from pretty much our inception.
  • Prior to this hespent 16 years at Capgemini where he sat on the UK Board and the European Management Team, responsible for some 1,200 people.
  • For the last 2 years, David has been instrumental in setting up and driving the success of Avida Global.

AVIDA Global Strengthens Management Team Following £1.9M Raise

Retrieved on: 
Tuesday, February 25, 2020
Organizations, International Bamboo and Rattan Organisation, Inbar, Avida, Articles

Dr. Inbar Maymon-Pomeranchik, one of the world's leading experts on medicinal cannabis, joins AVIDA Global's advisory board.

Key Points: 
  • Dr. Inbar Maymon-Pomeranchik, one of the world's leading experts on medicinal cannabis, joins AVIDA Global's advisory board.
  • Speaking of her role, David Kirby, CEO, AVIDA Global, said: "Dr. Inbar Maymon-Pomeranchik has been working with us from pretty much our inception.
  • Prior to this hespent 16 years at Capgemini where he sat on the UK Board and the European Management Team, responsible for some 1,200 people.
  • For the last 2 years, David has been instrumental in setting up and driving the success of Avida Global.